

**31**

(a) through (d) so as to obtain a homogeneous preparation of the polypeptide.

**23.** The method of claim **22** further comprising preparing a pharmaceutical composition by combining the homogeneous preparation of the polypeptide with a pharmaceutically acceptable carrier. 5

**32**

**24.** The method of claim **22** further comprising conjugating the purified polypeptide with a heterologous molecule.

**25.** The method of claim **24** wherein the heterologous molecule is polyethylene glycol, a label or a cytotoxic agent.

\* \* \* \* \*